Prevalence of Potential Drug-drug Interactions With Ritonavir-containing COVID-19 Therapy in the United States: An Analysis of the National Health and Nutrition Examination Survey

[1]  D. Kuritzkes,et al.  Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications , 2022, Clinical pharmacology and therapeutics.

[2]  V. Conti,et al.  Identification of Drug Interaction Adverse Events in Patients With COVID-19 , 2022, JAMA network open.

[3]  Sarvesh Sabarathinam,et al.  Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: A evidence-based review from six databases , 2022, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[4]  D. Kuritzkes,et al.  Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions , 2022, Annals of Internal Medicine.

[5]  A. Akkan,et al.  The Prevalence of Potential Drug-Drug Interactions in CKD-A Retrospective Observational Study of Cerrahpasa Nephrology Unit , 2022, Medicina.

[6]  H. J. Kim,et al.  Variable effects of underlying diseases on the prognosis of patients with COVID-19 , 2021, PloS one.

[7]  A. Khera,et al.  Corrigendum to U.S. Population at Increased Risk of Severe Illness from COVID-19 , 2021, American Journal of Preventive Cardiology.

[8]  K. Christensen,et al.  Burden and prevalence of risk factors for severe COVID-19 in the ageing European population – a SHARE-based analysis , 2021, Journal of Public Health.

[9]  A. Khera,et al.  U.S. population at increased risk of severe illness from COVID-19 , 2021, American Journal of Preventive Cardiology.

[10]  Taher Entezari-Maleki,et al.  Drug‐drug interactions with candidate medications used for COVID‐19 treatment: An overview , 2021, Pharmacology research & perspectives.

[11]  D. MacFadden,et al.  Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis , 2021, Clinical Microbiology and Infection.

[12]  D. Bloom,et al.  Social determinants of mortality from COVID-19: A simulation study using NHANES , 2021, PLoS medicine.

[13]  C. Marzolini,et al.  Drug interactions: a review of the unseen danger of experimental COVID-19 therapies , 2020, The Journal of antimicrobial chemotherapy.

[14]  M. Battegay,et al.  Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect , 2020, The Journal of antimicrobial chemotherapy.

[15]  A. Akbari,et al.  Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis , 2020, Archives of academic emergency medicine.

[16]  K. Demirkan,et al.  COVID-19 Drug Interactions , 2020 .

[17]  D. Qato,et al.  Prescription Medication Use Among Children and Adolescents in the United States , 2018, Pediatrics.

[18]  S. Setia,et al.  Drug–drug interactions involving antidepressants: focus on desvenlafaxine , 2018, Neuropsychiatric disease and treatment.

[19]  Q. Gu,et al.  Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012. , 2014, NCHS data brief.

[20]  H. Blume,et al.  Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update , 2014, Drug Safety.

[21]  M. Schwab,et al.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. , 2013, Pharmacology & therapeutics.

[22]  R. Mathijssen,et al.  Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs , 2013, British Journal of Cancer.

[23]  Shufeng Zhou,et al.  Clinically Important Drug Interactions Potentially Involving Mechanism-based Inhibition of Cytochrome P450 3A4 and the Role of Therapeutic Drug Monitoring , 2007, Therapeutic drug monitoring.

[24]  M. Feinleib.  National Center for Health Statistics (NCHS) , 2005 .